Societal CDMO, Inc. (SCTL)

NASDAQ: SCTL · IEX Real-Time Price · USD
1.090
0.00 (0.00%)
At close: Mar 27, 2024, 4:00 PM
1.080
-0.010 (-0.92%)
After-hours: Mar 27, 2024, 7:39 PM EDT

Company Description

Societal CDMO, Inc., a contract development and manufacturing organization, engages in the research and development, manufacturing, and packaging for various therapeutic dosage forms primarily in the small molecules in the United States and internationally.

It provides therapeutic development, end-to-end regulatory support, clinical and commercial manufacturing, aseptic fill/finish, lyophilization, packaging and logistics services to the global pharmaceutical market.

The company was formerly known as Recro Pharma, Inc. and changed its name to Societal CDMO, Inc. in March 2022.

Societal CDMO, Inc. was incorporated in 2007 and is based in Exton, Pennsylvania.

Societal CDMO, Inc.
Societal CDMO logo
Country United States
Founded 2007
IPO Date Mar 7, 2014
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 258
CEO J. David Enloe Jr.

Contact Details

Address:
1 E. Uwchlan Ave, Suite 112
Exton, Pennsylvania 19341
United States
Phone 770-534-8239
Website societalcdmo.com

Stock Details

Ticker Symbol SCTL
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001588972
CUSIP Number 75629F109
ISIN Number US75629F1093
Employer ID 26-1523233
SIC Code 2834

Key Executives

Name Position
Wayne B. Weisman J.D. Executive Chairman of the Board
J. David Enloe Jr. President, Chief Executive Officer and Director
Ryan D. Lake CPA Senior Vice President and Chief Financial Officer
Marshall Rizzo M.B.A. Senior Vice President and Chief Operating Officer
Richard Sidwell Ph.D. Senior Vice President and Chief Scientific Officer
Cristin Grove Vice President of Sales
Erica Raether M.A. Senior Vice President and Chief People Officer

Latest SEC Filings

Date Type Title
Mar 22, 2024 S-8 Securities to be offered to employees in employee benefit plans
Mar 22, 2024 S-8 Securities to be offered to employees in employee benefit plans
Mar 22, 2024 10-K Annual Report
Mar 18, 2024 SC 14D9/A Filing
Mar 18, 2024 SC TO-T/A Filing
Mar 15, 2024 8-K Current Report
Mar 11, 2024 SC 14D9 Filing
Mar 11, 2024 SC TO-T Filing
Mar 6, 2024 SC 13D General statement of acquisition of beneficial ownership
Feb 29, 2024 SC14D9C Filing